Evidence mapPaperPMID 40748348Full record

ArticleAlcohol, clinical & experimental research2025

Early signs of cardiovascular abnormalities in patients with alcohol misuse.

Lisa A Farinelli, Garrick Sherman, Daria Piacentino, Melanie L Schwandt, Valerie Espinal Abreu, Diane Cooper, Lorenzo Leggio

Abstract read
In one paragraph

Article in Alcohol, clinical & experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lisa A FarinelliClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland, USA.
Garrick ShermanOffice of the Clinical Director, National Institute on Drug Abuse, NIH, Baltimore, Maryland, USA.
Daria PiacentinoClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland, USA.
Melanie L SchwandtOffice of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, NIH, Bethesda, Maryland, USA.
Valerie Espinal AbreuClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland, USA.
Diane CooperOffice of Research Services, National Institutes of Health Library, National Institutes of Health, Bethesda, Maryland, USA.
Lorenzo LeggioClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-7284-8754

Funding

Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)ZIADA000635 · NATIONAL INSTITUTE ON DRUG ABUSE · 2025 to 2025
$2.7M
Intramural NIH HHS Z99 DA999999Intramural NIH HHS ZIA AA000218Intramural NIH HHS ZIA DA000635NIAAA NIH HHS ZIA-AA000218NIDA NIH HHS ZIA-DA000635
6 · The paper itself

Abstract

backgroundDeveloping integrative screening strategies to improve early identification of alcohol use disorder (AUD) is critical. This study examines cardiovascular parameters and alcohol-related phenotypes associated with two groups of alcohol drinkers: high-risk and low-risk.

methodsData from 520 high-risk and 586 low-risk non-smoking alcohol drinkers were analyzed. Generalized linear models analyzed the relationship between AUD-related outcomes (Alcohol Dependence Scale, number of DSM Alcohol Dependence criteria, Clinical Institute Withdrawal Assessment for Alcohol, Revised, and Penn Alcohol Craving Scale) and cardiovascular measures (mean arterial pressure, heart rate, QTcF, QRSD, and PR intervals, and QRS, P-wave, and T-wave axes). Multiple logistic regression examined associations of sociodemographic and cardiovascular variables with the odds of being a high-risk drinker. Statistically significant cardiovascular variables were retained as explanatory variables in Tweedie regression models for alcohol-related phenotypes. Interaction effects of risk group by cardiovascular measure were included in each model testing the association between cardiovascular parameters and alcohol-related phenotypes.

resultsHigher mean arterial pressure (MAP) and heart rate (HR) were associated with increased odds of high-risk drinking, while greater P-wave axis was associated with increased odds of low-risk drinking. Compared with low-risk drinkers, alcohol outcomes for those who engaged in high-risk drinking were not only significantly greater but also significantly less dependent on MAP and HR variations. The P-wave axis was significantly associated with low-risk drinking; however, it showed no significant association with any other alcohol outcomes.

conclusionsFindings from this study suggest that MAP, HR, and an abnormal P-wave axis can be useful signals for detecting increasing and potentially harmful alcohol drinking among patients who do not yet meet the threshold for high-risk drinking. Early, objective, and targeted identification can improve the current undertreatment of this population at risk by decreasing the interval between onset of AUD and initial clinical care and treatment.

Indexed as

AlcoholismCardiovascular DiseasesAdultAlcohol DrinkingFemaleHeart RateHumansMaleMiddle Agedalcohol use disorderblood pressurecardiac signscardiovascular healthelectrocardiogramharmful alcohol drinkingheart rate

Identifiers

PMID40748348
PMCPMC12321216

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.